Entities / Company
BioMarin Pharmaceutical.
American company
- Reports this week
- 1
- Active events
- 0
- Connections
- 100
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.Well supported7 reports
-
BioMarin Pharmaceutical filed a Form 13F with the SEC, coinciding with William Blair upgrading its stock rating.Some support1 report
-
BioMarin Pharmaceutical and CollPlant Biotechnologies were listed on Nasdaq and are being compared as healthcare companies.Some support2 reports
-
BioMarin Pharmaceutical and XTL Biopharmaceuticals are identified as healthcare companies competing for investment.Some support1 report
One to three months ago
-
Investors are comparing the financial performance metrics of BioMarin Pharmaceutical and Metagenomi.Some support1 report
-
MarketBeat aggregated analyst recommendations and price targets for BioMarin Pharmaceutical and Abeona Therapeutics Inc.Some support1 report
-
Applied DNA Sciences and BioMarin Pharmaceutical are identified as competing companies within the healthcare market.Some support2 reports
Gone quiet
No new reports in 90+ days-
BioMarin Pharmaceutical acquired Amicus, contributing to Q2 revenue growth.Some support4 reports
-
BioMarin Pharmaceutical filed a report with the Securities and Exchange Commission on July 24, 2026.Some support3 reports
-
Truist Financial upgraded BioMarin Pharmaceutical to strong-buy, and Morgan Stanley lowered its target price on the company's stock.Some support2 reports
-
BioMarin Pharmaceutical acquired Inozyme Pharma, Inc. on June 21, 2025.Some support5 reports
-
Trump pledged to unleash American oil and gas, leading to discussion of BioMarin Pharmaceutical's prospects through the lens of Benjamin Graham's investment philosophy.Some support3 reports1 development inside
-
BioCryst Pharmaceuticals is noted as benefiting from Trump-era tariffs on September 2, 2025.Some support4 reports1 development inside
-
Geode Capital Management raised its stake in BioMarin Pharmaceutical on June 18, 2026.Some support1 report
-
Ian Clark served as CEO of Genentech and was appointed to the BioMarin Pharmaceutical Board of Directors.Some support1 report
-
Barclays initiated a Buy rating on BioMarin Pharmaceutical, noting the company benefits from Trump-era tariffs.Speculative1 report
-
TD Cowen analysts questioned about revenue decline, while Goldman Sachs inquired about business development.Speculative1 report
-
BioMarin Pharmaceutical's product, valoctocogene roxaparvovec, is under scrutiny as analysts suggest AI stocks offer greater upside potential.Speculative2 reports
-
Morgan Stanley initiated coverage on July 11, 2025, with a Buy rating, noting that Voxzogo is BioMarin's therapy for achondroplasia and that TransCon CNP could be a competitor.Some support1 report
-
BioMarin Pharmaceutical develops therapies for rare genetic disorders.Some support1 report
-
Analysts set price targets for BioMarin Pharmaceutical stock on July 16, 2025.Some support2 reports
-
Alexander Hardy was appointed as the CEO of BioMarin Pharmaceutical.Some support1 report
-
Biogen's strong results hint at market expectations for BioMarin, positioning them as peers in the therapeutics segment.Some support4 reports
-
Automated Insights generated a story using company data related to BioMarin Pharmaceutical on August 5, 2025.Some support1 report
-
Bio-Techne, West Pharmaceutical Services, and BioMarin Pharmaceutical operate within the pharmaceutical supply chain, with WST providing packaging for injectable drugs.Some support1 report
-
Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical on August 12, 2025.Some support2 reports
-
BioMarin Pharmaceutical leadership stated on August 13, 2025, that the company is experiencing robust demand for its key therapies and noted an increase in net new U.S. patients.Some support1 report
-
BioMarin Pharmaceutical's stock fell while the S&P 500 climbed on August 20, 2025.Some support2 reports
-
Barclays maintained a Buy rating on BioMarin Pharmaceutical on August 23, 2025.Some support1 report
-
BioMarin Pharmaceutical is based in San Rafael, California.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around BioMarin Pharmaceutical this week
News at the entities that move BioMarin Pharmaceutical most-
Securities and Exchange Commission StructuralConnect Biopharma Holdings Limited filed disclosures with the SEC and its stock is traded on the Nasdaq exchange.Moves BioMarin Pharmaceutical
-
Morgan Stanley Mentioned togetherAmazon is attempting to challenge Google's search dominance while Morgan Stanley reports highlight shopper behavior trends.Moves BioMarin Pharmaceutical
-
Truist Financial Mentioned togetherSylvamo received rating updates from Bank of America, Truist Financial, and RBC on July 19, reiterating neutral ratings and lowering price targets.Moves BioMarin Pharmaceutical
-
Benzinga Mentioned togetherCullinan Therapeutics stock is listed on Nasdaq, as reported by Benzinga.Moves BioMarin Pharmaceutical
-
Geode Capital Management TransactionalGeode Capital Management, Mizuho Securities, and Manufacturers Life Insurance Company increased their holdings and raised their target price/rating on MBX Biosciences stock.Moves BioMarin Pharmaceutical
-
Royal Bank of Canada OperationalMorgan Stanley began coverage of Vylor with an 'overweight' rating, while Royal Bank of Canada authorized a $3.00 billion stock buyback plan.Moves BioMarin Pharmaceutical
Connections
The 22 strongest of 100, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Amicus Therapeutics Structural
BioMarin acquired Amicus Therapeutics, establishing a parent-subsidiary relationship and integrating its products.
-
Securities and Exchange Commission Structural
BioMarin Pharmaceutical is subject to regulatory oversight and mandatory reporting requirements by the Securities and Exchange Commission.
-
Amicus Structural
BioMarin acquired Amicus, establishing a structural relationship where Amicus's operations support BioMarin's revenue growth.
-
SEC Structural
BioMarin operates as a company under the formal regulatory oversight of the U.S. Securities and Exchange Commission.
-
Brian Mueller Structural
Brian Mueller serves as the Chief Financial Officer of BioMarin Pharmaceutical.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial analysis and target price recommendations for BioMarin Pharmaceutical stock.
-
Truist Financial Mentioned together
Truist Financial upgraded BioMarin Pharmaceutical to a strong-buy rating.
-
valoctocogene roxaparvovec Structural
BioMarin Pharmaceutical is the developer and presenter of data regarding the product valoctocogene roxaparvovec.
Show all 22 connections
-
Geode Capital Management Transactional
Geode Capital Management raised its stake in BioMarin Pharmaceutical.
-
Amgen Operational
The two companies actively compete within the therapeutics segment of the biopharmaceutical market.
-
Benzinga Mentioned together
Benzinga provides financial reporting, stock updates, and analyst coverage for BioMarin Pharmaceutical.
-
Applied DNA Sciences Operational
Both companies are actively competing against each other within the broader healthcare market and are frequently compared by investors.
-
Gilead Sciences Operational
Both companies are identified as peers and active competitors within the therapeutics segment.
-
Nasdaq Shared context
BioMarin Pharmaceutical is listed and trades on the Nasdaq exchange.
-
MarketBeat Mentioned together
MarketBeat reports and aggregates professional market sentiment and ratings for BioMarin Pharmaceutical.
-
Biogen Mentioned together
The companies are co-mentioned as peers operating within the therapeutics segment.
-
Citigroup Mentioned together
Citigroup provides financial ratings and price target updates for BioMarin stock.
-
San Rafael Shared context
BioMarin Pharmaceutical is located in San Rafael.
-
Royal Bank of Canada Operational
Royal Bank of Canada analysts have issued reduced price objectives for BioMarin Pharmaceutical stock.
-
Bank of America Mentioned together
No evidence was provided to establish a relationship between Bank of America and BioMarin Pharmaceutical.
-
Joseph Schwartz Mentioned together
The provided evidence only discusses BioMarin Pharmaceutical and does not mention Joseph Schwartz.
-
William P. Blair Mentioned together
A single snapshot mentions B upgrading a stock rating, but does not explicitly link this action to A.
History
Events by the month they beganNovember 2026
2 eventsOctober 2026
1 eventSeptember 2026
3 events- Investors are comparing the financial performance metrics of BioMarin Pharmaceutical and Metagenomi.
- MarketBeat aggregated analyst recommendations and price targets for BioMarin Pharmaceutical and Abeona Therapeutics Inc.
- Applied DNA Sciences and BioMarin Pharmaceutical are identified as competing companies within the healthcare market.
Show 3 earlier months
August 2026
1 eventJuly 2026
3 events- BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.
- BioMarin Pharmaceutical filed a report with the Securities and Exchange Commission on July 24, 2026.
- Truist Financial upgraded BioMarin Pharmaceutical to strong-buy, and Morgan Stanley lowered its target price on the company's stock.
June 2026
20 events- BioMarin Pharmaceutical acquired Inozyme Pharma, Inc. on June 21, 2025.
- Trump pledged to unleash American oil and gas, leading to discussion of BioMarin Pharmaceutical's prospects through the lens of Benjamin Graham's investment philosophy.
- BioCryst Pharmaceuticals is noted as benefiting from Trump-era tariffs on September 2, 2025.
- Geode Capital Management raised its stake in BioMarin Pharmaceutical on June 18, 2026.
- Ian Clark served as CEO of Genentech and was appointed to the BioMarin Pharmaceutical Board of Directors.
- Barclays initiated a Buy rating on BioMarin Pharmaceutical, noting the company benefits from Trump-era tariffs.
- TD Cowen analysts questioned about revenue decline, while Goldman Sachs inquired about business development.
- BioMarin Pharmaceutical's product, valoctocogene roxaparvovec, is under scrutiny as analysts suggest AI stocks offer greater upside potential.
- Morgan Stanley initiated coverage on July 11, 2025, with a Buy rating, noting that Voxzogo is BioMarin's therapy for achondroplasia and that TransCon CNP could be a competitor.
- BioMarin Pharmaceutical develops therapies for rare genetic disorders.
- Analysts set price targets for BioMarin Pharmaceutical stock on July 16, 2025.
- Alexander Hardy was appointed as the CEO of BioMarin Pharmaceutical.
- Biogen's strong results hint at market expectations for BioMarin, positioning them as peers in the therapeutics segment.
- Automated Insights generated a story using company data related to BioMarin Pharmaceutical on August 5, 2025.
- Bio-Techne, West Pharmaceutical Services, and BioMarin Pharmaceutical operate within the pharmaceutical supply chain, with WST providing packaging for injectable drugs.
- Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical on August 12, 2025.
- BioMarin Pharmaceutical leadership stated on August 13, 2025, that the company is experiencing robust demand for its key therapies and noted an increase in net new U.S. patients.
- BioMarin Pharmaceutical's stock fell while the S&P 500 climbed on August 20, 2025.
- Barclays maintained a Buy rating on BioMarin Pharmaceutical on August 23, 2025.
- BioMarin Pharmaceutical is based in San Rafael, California.